Promising results from preclinical studies reported that pioglitazone and rosiglitazone are able to ameliorate memory and cognitive impairment and decrease AD-related pathology in several rodent models of AD, including the 3xTg-AD mice and Tg2576 mice, by enhancing AKT signaling and attenuating tau hyperphosphorylation, neuroinflammation, and AD pathology [254,255,256,257]. This evidence concerns the gene MAPT and Cognitive impairment.